| Correlation of e antigen, DNA polymerase activity, and Dane particles in chronic benign and chronic active type B hepatitis infections. |
Tong MJ, Stevenson D, Gordon I |
1977 |
| Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. |
Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H |
1994 |
| Ionic requirements of the DNA polymerase associated with serum hepatitis B antigen. |
Hirschman SZ, Garfinkel E |
1977 |
| Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. |
Schmit I, Boivin G |
1999 |
| Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. |
Maeda Y, Venzon DJ, Mitsuya H |
1998 |
| Discordant e antigen, DNA polymerase activity, and Dane particle responses in two patients representing an index case-contact case pair with hepatitis B virus infection. |
Perrillo RP, Gelb LD, Milligan WH, Wellinghoff W, Aach RD |
1977 |
| Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. |
Brumme ZL, Brumme CJ, Chui CK, Mo T, Wynhoven B, Woods CK, Henrick BM, Hogg RS, Montaner JS, Harrigan PR |
2007 |
| Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. |
Chang LY, Chiang BL, Kao CL, Wu MH, Chen PJ, Berkhout B, Yang HC, Huang LM |
2006 |
| Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. |
Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM |
1999 |
| Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. |
Miller MD, Margot NA, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M |
2004 |
| e antigen and antibody, DNA polymerase, and inhibitors of DNA polymerase in acute and chronic hepatitis. |
Cappel R, DeCuyper F, Van Beers D |
1977 |
| Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. |
Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder BA |
2000 |
| Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). |
Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C |
1995 |
| Filtration and immunoprecipitation in the elimination of DNA polymerase activity associated with bacterial contamination of sera positive for hepatitis B e antigen and its corresponding antibody. |
Perrillo RP, Gelb LD, Wellinghoff W, Aach RD |
1978 |
| A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. |
Tatarowicz WA, Lurain NS, Thompson KD |
1992 |
| Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. |
Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL |
2003 |
| Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. |
De Antoni A, Foli A, Lisziewicz J, Lori F |
1997 |
| Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. |
Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, Oka S |
2007 |